In this group, dose-corrected ESC concentrations were higher compared to patients without (n = 51) liver dysfunctions identified by GGT and AST/ALT ratio (p = 0.013; mean 2.23 ± 0.27 vs. 1.51 ± 0.12 ng/mL/ mg/day). The gene discussed is GPT; the disease is Decreased liver function.